News
News
Local News
Crime & Public Safety
Your Tax Dollars At Work
Politics
Massachusetts
Nation
World
Business
Health
Weather
Columnists
Traffic
Sports
Sports
Red Sox
Patriots
Celtics
Bruins
College
High School
More Sports
Scores & Stats
Entertainment
Entertainment
Celebrity News
Arts & Culture
Movies
Television
Music
Fun & Games
Horoscope
Lottery
Comics
Puzzles
Lifestyle
Lifestyle
Food & Beverage
Travel
Style & Fashion
Obituaries
Obituaries
Local Obituaries
Submit an Obituary
Opinion
Opinion
Editorials
Op-Ed
Letters
Submit a Letter
Radio
Weather
E-Edition
Subscribe
Sign Up For Newsletters
News
News
Local News
Crime & Public Safety
Your Tax Dollars At Work
Politics
Massachusetts
Nation
World
Business
Health
Weather
Columnists
Traffic
Sports
Sports
Red Sox
Patriots
Celtics
Bruins
College
High School
More Sports
Scores & Stats
Entertainment
Entertainment
Celebrity News
Arts & Culture
Movies
Television
Music
Fun & Games
Horoscope
Lottery
Comics
Puzzles
Lifestyle
Lifestyle
Food & Beverage
Travel
Style & Fashion
Obituaries
Obituaries
Local Obituaries
Submit an Obituary
Opinion
Opinion
Editorials
Op-Ed
Letters
Submit a Letter
Radio
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Science 37, Inc.
Science 37 Enrolls 42% of Trial Cohort in 8 Weeks
July 18, 2024
From
Science 37, Inc.
Via
GlobeNewswire
Science 37 Quickly Impacts Performance in Under-Enrolling Clinical Trials
June 27, 2024
From
Science 37, Inc.
Via
GlobeNewswire
CORRECTION-- Science 37 Surpasses Enrollment Goals, Accelerates Phase 2 Rare Disease Clinical Trial
June 12, 2024
From
Science 37, Inc.
Via
GlobeNewswire
Science 37 Surpasses Enrollment Goals, Accelerates Phase 2 Rare Disease Clinical Trial
June 12, 2024
From
Science 37, Inc.
Via
GlobeNewswire
Science 37 Metasite™ Undergoes Successful FDA Inspection, Marking Major Milestone in Virtual Site Quality Assurance and Compliance
May 13, 2024
From
Science 37, Inc.
Via
GlobeNewswire
Tickers
SNCE
Science 37 Wins 2024 MedTech Breakthrough Award for “Clinical Efficiency Innovation”
May 09, 2024
From
Science 37, Inc.
Via
GlobeNewswire
Tickers
SNCE
Science 37 Delivers 22x Faster Enrollment than Traditional Methods in Phase 3 Asthma Clinical Trial
May 02, 2024
From
Science 37, Inc.
Via
GlobeNewswire
Tickers
SNCE
Science 37 Provides Fully Consented Patients to Sites to Supplement Enrollment
April 17, 2024
From
Science 37, Inc.
Via
GlobeNewswire
Tickers
SNCE
Science 37 to be Acquired by eMed, Expanding Access to Patients and Accelerating Enrollment
January 29, 2024
From
Science 37, Inc.
Via
GlobeNewswire
Tickers
SNCE
Science 37 Receives Top Honors in Everest PEAK Matrix®
December 12, 2023
From
Science 37, Inc.
Via
GlobeNewswire
Tickers
SNCE
Science 37 Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
December 07, 2023
From
Science 37, Inc.
Via
GlobeNewswire
Tickers
SNCE
Science 37 Holdings, Inc. Announces 1-for-20 Reverse Stock Split effective December 8, 2023
December 05, 2023
From
Science 37, Inc.
Via
GlobeNewswire
Tickers
SNCE
Science 37 Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
November 10, 2023
From
Science 37, Inc.
Via
GlobeNewswire
Tickers
SNCE
Science 37 Reports Third Quarter 2023 Financial Results
November 07, 2023
From
Science 37, Inc.
Via
GlobeNewswire
Tickers
SNCE
Science 37 to Report Third Quarter 2023 Financial Results on November 7, 2023
October 24, 2023
From
Science 37, Inc.
Via
GlobeNewswire
Tickers
SNCE
Science 37 Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
October 06, 2023
From
Science 37, Inc.
Via
GlobeNewswire
Tickers
SNCE
Science 37 Chief Delivery Officer, Darcy Forman, Named to Prestigious PharmaVoice 100 List
September 20, 2023
From
Science 37, Inc.
Via
GlobeNewswire
Tickers
SNCE
Science 37 Recognized in the Gartner® Hype Cycle™ for Life Science Clinical Development, 2023
September 13, 2023
From
Science 37, Inc.
Via
GlobeNewswire
Tickers
SNCE
Science 37 Named Market Leader for Global Decentralized Clinical Trials by Frost & Sullivan
September 12, 2023
From
Science 37, Inc.
Via
GlobeNewswire
Tickers
SNCE
Science 37 to Participate in H.C. Wainwright 25th Annual Global Investment Conference
September 05, 2023
From
Science 37, Inc.
Via
GlobeNewswire
Tickers
SNCE
Science 37 Recognized as Best Digital Health Solution Nominee at 2023 Prix Galien USA Awards
August 15, 2023
From
Science 37, Inc.
Via
GlobeNewswire
Tickers
SNCE
Science 37 Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
August 11, 2023
From
Science 37, Inc.
Via
GlobeNewswire
Tickers
SNCE
Science 37 Reports Second Quarter 2023 Financial Results
August 08, 2023
From
Science 37, Inc.
Via
GlobeNewswire
Tickers
SNCE
Science 37 to Report Second Quarter 2023 Financial Results on August 8, 2023
July 25, 2023
From
Science 37, Inc.
Via
GlobeNewswire
Tickers
SNCE
Synlogic Partners with Science 37 on Pivotal Study for Investigational Drug for Phenylketonuria (PKU)
July 11, 2023
From
Science 37, Inc.
Via
GlobeNewswire
Tickers
SNCE
Science 37 Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
July 07, 2023
From
Science 37, Inc.
Via
GlobeNewswire
Tickers
SNCE
Science 37 Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
June 09, 2023
From
Science 37, Inc.
Via
GlobeNewswire
Tickers
SNCE
Science 37 Wins 2023 MedTech Breakthrough Award for "Best Overall Clinical Trial Platform"
May 18, 2023
From
Science 37, Inc.
Via
GlobeNewswire
Tickers
SNCE
Science 37 Reports First Quarter 2023 Financial Results
May 15, 2023
From
Science 37, Inc.
Via
GlobeNewswire
Tickers
SNCE
Science 37 Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
May 05, 2023
From
Science 37, Inc.
Via
GlobeNewswire
Tickers
SNCE
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
Close